Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases
Author:
Publisher
Wiley
Subject
Dermatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2133.2006.07523.x/fullpdf
Reference19 articles.
1. WHO-EORTC classification for cutaneous lymphomas;Willemze;Blood,2005
2. Primary cutaneous B-cell lymphoma: review and current concepts;Pandolfino;J Clin Oncol,2000
3. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance;Smith;Oncogene,2003
4. From the bench to the bedside: ways to improve rituximab efficacy;Cartron;Blood,2004
5. Use of rituximab, the new FDA-approved antibody;Leget;Curr Opin Oncol,1998
Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cutaneous B-Cell Lymphomas;Hematology/Oncology Clinics of North America;2024-10
2. Intralesional and systemic rituximab in the treatment of primary cutaneous B‐cell lymphoma;JEADV Clinical Practice;2023-06-23
3. What is new about primary cutaneous B cell lymphomas;Italian Journal of Dermatology and Venereology;2023-06
4. Off-Label Uses of Rituximab in Dermatology;Current Dermatology Reports;2022-10-06
5. Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas;American Journal of Clinical Dermatology;2022-07-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3